Product Description: Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Tim Harrison, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151./[2]Ian D Pavord, From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022 Mar;77(3):778-797./[3]P Zia-Amirhosseini, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7.
CAS Number: 196078-29-2
Molecular Weight: (146.24 kDa)
Compound Purity: 97.50
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related
English
Deutsch
